• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Company halts study of IC drug due to positive results

Article

Urigen Pharmaceuticals has announced the early closure of its study of a drug known as URG101 due to positive, statistically significant interim analysis results in both the primary and all secondary endpoints. Top-line results of the interim analysis, which was planned at 50% enrollment, were previously released March 12.

Urigen Pharmaceuticals has announced the early closure of its study of a drug known as URG101 due to positive, statistically significant interim analysis results in both the primary and all secondary endpoints. Top-line results of the interim analysis, which was planned at 50% enrollment, were previously released March 12.

The URG101-104 study was a pharmacodynamic and safety study investigating the treatment of painful bladder syndrome/interstitial cystitis. According to the manufacturer, the study design provided sufficient power to reliably assess treatment effects across modestly sized cohorts; thus, continuing enrollment would not meaningfully alter the study conclusions of safety and tolerability. Accelerated development of the drug is anticipated.

Related Videos
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.